ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,070.40
-0.05%
S&P 500
5,303.27
0.12%
US Dollar vs CAD
1.36105
-0.03%
Bitcoin
66,801.29
2.39%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Theseus Pharmaceuticals Inc (THRX)

  7. Theseus Pharmaceuticals Inc (THRX) News

THRX

Theseus Pharmaceuticals (THRX)

Theseus Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:THRX
DateTimeSourceHeadlineSymbolCompany
02/26/20248:00AMEdgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:THRXTheseus Pharmaceuticals Inc
02/15/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:THRXTheseus Pharmaceuticals Inc
02/14/20243:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:THRXTheseus Pharmaceuticals Inc
02/14/20241:26PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:THRXTheseus Pharmaceuticals Inc
02/14/20241:24PMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:THRXTheseus Pharmaceuticals Inc
02/14/20241:22PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:THRXTheseus Pharmaceuticals Inc
02/14/20249:44AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
02/14/20249:35AMEdgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
02/14/20247:30AMPR Newswire (US)Theseus Pharmaceuticals Announces Closing of Tender OfferNASDAQ:THRXTheseus Pharmaceuticals Inc
02/13/202411:36AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
02/07/20244:21PMEdgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
02/07/20244:15PMEdgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
01/30/20247:52AMEdgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
01/30/20247:23AMEdgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
01/30/20247:00AMBusiness WireConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsNASDAQ:THRXTheseus Pharmaceuticals Inc
01/10/20248:47AMEdgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:THRXTheseus Pharmaceuticals Inc
01/10/20247:51AMEdgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:THRXTheseus Pharmaceuticals Inc
12/22/20235:52AMEdgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:THRXTheseus Pharmaceuticals Inc
12/22/20235:36AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
12/22/20235:30AMPR Newswire (US)Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightNASDAQ:THRXTheseus Pharmaceuticals Inc
12/04/20235:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
11/27/20235:37AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
11/27/20235:30AMPR Newswire (US)Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCNASDAQ:THRXTheseus Pharmaceuticals Inc
11/24/20233:23PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
11/17/20233:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:THRXTheseus Pharmaceuticals Inc
11/15/20236:00AMEdgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:THRXTheseus Pharmaceuticals Inc
11/13/20233:05PMPR Newswire (US)Theseus Pharmaceuticals Announces Process to Explore Strategic AlternativesNASDAQ:THRXTheseus Pharmaceuticals Inc
11/07/20233:05PMPR Newswire (US)Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare ConferenceNASDAQ:THRXTheseus Pharmaceuticals Inc
11/07/20233:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:THRXTheseus Pharmaceuticals Inc
10/31/20233:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:THRX

Your Recent History

NYSE
FCX-CL
EU
H822S
H822S
USOTC
ITEC
Intertech Solutions (CE)
COIN
REMITEUR
NASDAQ
SNTS
Santarus
LSE
TSEG
TSE Group
TSX
SBT.B
Purpose Silver Bullion
BIT
UC610M
Unicredit Bank
EU
INWRD
Hsbc WRD iNav
LSE
43OE
Hsbc Bk. 24
USOTC
APYP
Appyea (QB)
MRTX
NAVYETH
BoatPilot Token
COIN
TRUMPUSD
YUGE
TSXV
LBY
Liberty One Lithium
EU
EBUY
Lyxor Asset Management L...
BIT
F17522
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved